GlassScriptPhysician profile
Deborah T Combs-Cantrell
NPI 1326144304
$134,809.86
in general payments reported to CMS, 2019-2025
51 companies · $19K in 2025
The $19K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $19K · 2021: $22K · 2022: $24K · 2023: $17K · 2024: $18K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $11K · Travel and Lodging: $183 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,522.50 |
| Food and Beverage | $11,459.50 |
| Travel and Lodging | $182.51 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42,941.62 | 2021-2025 | Ubrelvy, Qulipta |
| Sk Life Science, INC. | $25,753.47 | 2020-2025 | |
| Ucb, INC. | $23,892.28 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Eisai INC. | $10,368.27 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,928.72 | 2022 | |
| Supernus Pharmaceuticals, INC. | $4,463.21 | 2019-2022 | |
| Pfizer INC. | $4,177.58 | 2019-2025 | |
| Allergan, INC. | $1,938.82 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $1,662.53 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Amgen INC. | $1,178.02 | 2019-2023 | Aimovig |
| Livanova USA, INC. | $1,107.13 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Lilly USA, LLC | $1,060.92 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Genzyme Corporation | $939.29 | 2019-2023 | |
| Biogen, INC. | $933.53 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Grifols USA, LLC | $865.00 | 2019-2025 | Gamunex-C, Xembify |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $779.20 | 2020-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $759.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $563.46 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $548.94 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $495.00 | 2019 | |
| Axsome Therapeutics, INC. | $337.13 | 2023-2025 | Sunosi, Symbravo |
| Corium, LLC | $328.41 | 2023 | Adlarity |
| Sumitomo Pharma America, INC. | $325.66 | 2024 | Aptiom |
| Aucta Pharmaceuticals, INC. | $325.08 | 2024-2025 | Motpoly Xr |
| Celgene Corporation | $313.70 | 2021-2025 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $289.21 | 2020-2021 | |
| Catalyst Pharmaceuticals, INC. | $250.00 | 2023-2025 | Fycompa |
| Neurelis, INC. | $226.90 | 2020-2025 | Valtoco |
| Genentech USA, INC. | $222.22 | 2019-2021 | |
| Almatica Pharma LLC | $182.44 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $167.86 | 2019 | |
| Alexion Pharmaceuticals, INC. | $144.95 | 2019 | |
| Assertio Therapeutics, INC. | $120.03 | 2019-2020 | |
| Neuropace, INC. | $119.73 | 2024-2025 | |
| Acorda Therapeutics, INC | $115.65 | 2019-2023 | Inbrija |
| Greenwich Biosciences, INC. | $114.46 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $112.45 | 2022-2023 | Ponvory |
| Ani Pharmaceuticals, INC. | $105.24 | 2024 | Purified Cortrophin Gel |
| Aquestive Therapeutics, INC. | $93.61 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $77.42 | 2021 | |
| Akcea Therapeutics, INC. | $70.84 | 2019 | |
| Csl Behring | $67.02 | 2019-2025 | Hizentra |
| Upsher-Smith Laboratories LLC | $59.76 | 2020-2022 | |
| Ge Healthcare | $57.14 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $56.56 | 2023-2025 | Rexulti |
| Octapharma USA, INC. | $52.16 | 2023-2025 | Panzyga |
| Kyowa Kirin, INC. | $43.18 | 2021-2022 | |
| Medtronic, INC. | $23.40 | 2023 | Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $22.80 | 2023 | Keveyis |
| Impel Pharmaceuticals INC. | $14.77 | 2023 | Trudhesa |
| Strongbridge US INC. | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Combs-Cantrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.